Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.
Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the leading cause of treatment failure in high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), yet effective maintenance strategies are currently lacking. The combination of chidamide (CHI) and venetoclax (VEN) represents a novel approach.
Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the leading cause of treatment failure in high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), yet effective maintenance strategies are currently lacking. The combination of chidamide (CHI) and venetoclax (VEN) represents a novel approach.
What the study was
- Study design
- Journal Article (unspecified)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Ann Hematol
Why it surfaced
Matched watchlist topic 'Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)'. Study design: Journal Article (unspecified). Score: 8/10 (N:3, R:3, D:1, P:1).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.